Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds JP Morgan Downgrades Cyteir Therapeutics to Neutral

JP Morgan Downgrades Cyteir Therapeutics to Neutral

JP Morgan analyst Anupam Rama downgrades Cyteir Therapeutics (NASDAQ:CYT) from Overweight to Neutral.

byBenzinga Newsdesk

January 20, 2023

1 minute read

JP Morgan analyst Anupam Rama downgrades Cyteir Therapeutics (NASDAQ:CYT) from Overweight to Neutral.

Mizuho Reinstates Neutral on Intel, Announces $32 Price Target

By Benzinga Newsdesk

November 22, 8:23 AM

Mizuho analyst Vijay Rakesh reinstates Intel (NASDAQ:INTC) with a Neutral and announces $32 price target.

INTC

Why EV-Maker Srivaru Stock Is Charging Higher

By Erica Kollmann

June 14, 10:01 AM

SRIVARU Holding shares are trading higher Friday after the company announced it will begin accepting paid reservations and bookings for its flagship product, the PRANA 2.0, on June 16.

SVMH

Bitcoin Rises Above $26,000 Following Inflation Data; Terra Classic Emerges As Top Gainer

By Lisa Levin

June 13, 9:36 AM

Bitcoin (CRYPTO: BTC) traded higher, with the cryptocurrency prices trading above the $26,000 level on Tuesday. Ethereum (CRYPTO: ETH) also edged higher, but traded below the key $1,800 mark this morning.

$APE

IGM Biosciences: Q2 Earnings Insights

By Benzinga Insights

August 8, 11:27 PM

IGM Biosciences (NASDAQ:IGMS) reported its Q2 earnings results on Monday, August 8, 2022 at 04:10 PM. Here's what investors need to know about the announcement.

IGMS

JP Morgan Downgrades Cyteir Therapeutics to Neutral

Related Posts

Mizuho Reinstates Neutral on Intel, Announces $32 Price Target

Why EV-Maker Srivaru Stock Is Charging Higher

Bitcoin Rises Above $26,000 Following Inflation Data; Terra Classic Emerges As Top Gainer

IGM Biosciences: Q2 Earnings Insights